Viktor Zarev

Viktor Zarev

InvestorPlace Contributor

Expertise: Science, Technology, Defense, and Medicine Stock Review

Education: BS in Biology from Baylor University, MS in Computer Science from Pace University

Viktor Zarev is a Freelance Writer at InvestorPlace.com, where he aims to elucidate and simplify the world of high-tech stocks and cryptocurrencies. To accomplish this, Viktor specializes in distilling the most pertinent and critical details for investors to focus on.

He also writes in-depth research scripts for defense documentaries on YouTube as well as creative direction and copywriting for game studios. He is also a supply chain specialist in the defense industry.

Viktor holds a BS in Global Health Biology from Baylor University, where he graduated on the Medical Entomology Research Track, studying flaviviruses and developing vector control methods. He is currently earning an MS in Computer Science from Pace University, focusing on artificial intelligence and machine learning.

Recent Articles

3 Healthcare Stocks Positioned for Possible Market Outperformance

By Viktor Zarev, InvestorPlace Contributor

While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market.

3 Blue-Chip Stocks to Sell in August Before They Crash & Burn

By Viktor Zarev, InvestorPlace Contributor

Knowing which blue-chip stocks to sell is critical during a market downturn like the one investors are currently facing.

The 3 Best Edge Computing Stocks to Buy in August 2024

By Viktor Zarev, InvestorPlace Contributor

Investors might want to keep an eye on the best edge computing stocks on the market as the industry is projected to grow to $16.45 billion.

3 Genomics Stocks That May Transform Personalized Medicine 

By Viktor Zarev, InvestorPlace Contributor

These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.

3 Biotech Stocks to Sell in August Before They Crash & Burn

By Viktor Zarev, InvestorPlace Contributor

Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.

Load More